These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35563085)

  • 1. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
    Katagiri S; Chi S; Minami Y; Fukushima K; Shibayama H; Hosono N; Yamauchi T; Morishita T; Kondo T; Yanada M; Yamamoto K; Kuroda J; Usuki K; Akahane D; Gotoh A
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
    Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.
    Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT
    J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
    Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
    Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
    Obata Y; Hara Y; Shiina I; Murata T; Tasaki Y; Suzuki K; Ito K; Tsugawa S; Yamawaki K; Takahashi T; Okamoto K; Nishida T; Abe R
    Cell Commun Signal; 2019 Sep; 17(1):114. PubMed ID: 31484543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
    Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
    Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.
    Tsujimura A; Kiyoi H; Shiotsu Y; Ishikawa Y; Mori Y; Ishida H; Toki T; Ito E; Naoe T
    Int J Hematol; 2010 Nov; 92(4):624-33. PubMed ID: 20890793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
    Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
    Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
    Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
    Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.
    Abbaspour Babaei M; Kamalidehghan B; Saleem M; Huri HZ; Ahmadipour F
    Drug Des Devel Ther; 2016; 10():2443-59. PubMed ID: 27536065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
    Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
    Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
    Sritana N; Auewarakul CU
    Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
    Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
    Heo SK; Noh EK; Kim JY; Jeong YK; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
    Sci Rep; 2017 Nov; 7(1):15278. PubMed ID: 29127384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
    Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].
    Goryainova NV
    Lik Sprava; 2014 Dec; (12):10-8. PubMed ID: 26638462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.